Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Conditions: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms Sponsors: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer & Oncology | Carcinoma | Chemotherapy | Non-Small Cell Lung Cancer | Research | Respiratory Medicine